Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors

HIGHLIGHTS

• who: Takuma Matoba from the DepartmentCity University have published the research work: Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors, in the Journal: Scientific Reports Scientific Reports of November/30,/2021
• what: The authors evaluated the impact of BNML, BSLD, and SUVmax on clinical outcomes in patients with RM-HNC treated with ICIs; the analyses identified high BNML, high BSLD, and high SUVmax as risk factors for worse survival rates and worse disease control rates.
• how: This study was conducted . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.